dr. marcia brose on lenvatinib in differentiated thyroid cancer
Published 9 years ago • 342 plays • Length 1:10Download video MP4
Download video MP3
Similar videos
-
2:47
dr. brose discusses lenvatinib and sorafenib in differentiated thyroid cancer
-
1:17
dr. marcia brose discusses lenvatinib as a new option in dtc
-
1:23
dr. brose discusses lenvatinib for the treatment of patients with thyroid cancer
-
1:59
dr. marcia brose describes sorafenib in rai-resistant differentiated thyroid cancer
-
2:52
effect of age and lenvatinib on os in thyroid cancer
-
1:18
dr. marcia brose on sorafenib in radioactive iodine-resistant thyroid cancer
-
21:13
advances in the management of iodine refractory thyroid cancers- dr. marcia brose
-
1:09
dr. brose discusses the tolerability of sorafenib in thyroid cancer
-
1:56
dr. brose on vandetanib for differentiated thyroid cancer
-
9:03
sequencing therapies for differentiated thyroid cancer
-
3:32
24mg versus 18mg starting dose of lenvatinib for differentiated thyroid cancer
-
1:14
dr. brose on recent advances in papillary thyroid cancer
-
9:23
marcia s. brose, md, phd: all about thyroid cancer
-
0:45
dr. brose describes the decision trial
-
1:20
dr. brose discusses braf mutations in thyroid cancer
-
2:15
effect of age on lenvatinib on os for pts w/ 131i-refractory thyroid cancer
-
0:57
dr. brose describes the decision trial
-
1:02
dr. brose discusses updated overall survival analysis of the decision trial
-
1:00
lenvatinib in thyroid cancer with and without vegf-targeted therapy